Athersys, Inc. (NASDAQ:ATHX) received a $12.00 target price from research analysts at Maxim Group in a research note issued on Monday. The firm presently has a “buy” rating on the biopharmaceutical company’s stock.

Shares of Athersys (NASDAQ:ATHX) opened at 1.50 on Monday. The stock’s market cap is $166.97 million. Athersys has a 12-month low of $1.02 and a 12-month high of $2.30. The company has a 50 day moving average price of $1.59 and a 200 day moving average price of $1.41.

Athersys (NASDAQ:ATHX) last issued its earnings results on Tuesday, May 9th. The biopharmaceutical company reported ($0.06) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.07) by $0.01. Athersys had a negative return on equity of 135.04% and a negative net margin of 765.65%. The firm had revenue of $1.50 million for the quarter, compared to analysts’ expectations of $0.45 million. During the same quarter last year, the firm earned $0.06 earnings per share. The firm’s revenue for the quarter was down 90.3% compared to the same quarter last year. Analysts anticipate that Athersys will post ($0.26) earnings per share for the current fiscal year.

TRADEMARK VIOLATION WARNING: This piece was first posted by American Banking News and is the property of of American Banking News. If you are accessing this piece on another website, it was copied illegally and reposted in violation of international trademark and copyright laws. The correct version of this piece can be viewed at https://www.americanbankingnews.com/2017/08/07/maxim-group-analysts-give-athersys-inc-athx-a-9-00-price-target.html.

In related news, EVP John J. Harrington sold 36,000 shares of Athersys stock in a transaction on Friday, June 16th. The stock was sold at an average price of $1.45, for a total value of $52,200.00. Following the transaction, the executive vice president now owns 712,743 shares in the company, valued at $1,033,477.35. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 9.40% of the stock is currently owned by company insiders.

A number of hedge funds and other institutional investors have recently modified their holdings of ATHX. Vanguard Group Inc. boosted its position in shares of Athersys by 19.5% in the first quarter. Vanguard Group Inc. now owns 3,899,200 shares of the biopharmaceutical company’s stock worth $6,668,000 after buying an additional 637,322 shares during the last quarter. State Street Corp boosted its position in shares of Athersys by 1.9% in the fourth quarter. State Street Corp now owns 1,119,590 shares of the biopharmaceutical company’s stock worth $1,714,000 after buying an additional 20,680 shares during the last quarter. Geode Capital Management LLC boosted its position in shares of Athersys by 35.2% in the first quarter. Geode Capital Management LLC now owns 756,004 shares of the biopharmaceutical company’s stock worth $1,292,000 after buying an additional 196,981 shares during the last quarter. Russell Investments Group Ltd. purchased a new position in shares of Athersys during the fourth quarter worth $617,000. Finally, Old Mutual Global Investors UK Ltd. purchased a new position in shares of Athersys during the first quarter worth $530,000. Hedge funds and other institutional investors own 17.75% of the company’s stock.

About Athersys

Athersys, Inc is an international biotechnology company that is focused primarily in the field of regenerative medicine. The Company’s MultiStem cell therapy, an allogeneic stem cell product, is its lead platform product and is in later-stage clinical development. Its clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the standard of care is limited or inadequate for many patients.

Receive News & Ratings for Athersys Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Athersys Inc. and related companies with MarketBeat.com's FREE daily email newsletter.